Stifel analyst Rick Wise lowered the firm’s price target on Zimmer Biomet (ZBH) to $115 from $138 and keeps a Buy rating on the shares. Zimmer delivered “an overall positive 2025 start,” with better-than-expected Q1 sales and EPS, but the firm’s 2026 EPS estimate was lowered to $8.00 from $8.70 in the absence of clearer 2026 tariff-related guidance, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Cautious Outlook for Zimmer Biomet Holdings Amid Tariff Exposure and Conservative Guidance
- Zimmer Biomet Reports Q1 2025 Financial Results
- Zimmer Biomet’s Earnings Call: Mixed Sentiments Amid Growth
- Zimmer Biomet price target lowered to $104 from $119 at TD Cowen
- Zimmer Biomet price target lowered to $112 from $125 at RBC Capital